The 38th European Association of Urology (EAU23) Annual Meeting took place from March 10th to 13th, 2023, in Milan, Italy, the fashion capital of the world. The EAU Annual Meeting is one of the most closely watched urological conferences in Europe and even globally, attracting over 15,000 urology experts from around the world each year. At this conference, West China Hospital of Sichuan University reported Several studies.
Abstract Number: A1059
M7G-related lncRNA Prognostic Index Can Predict the Prognosis and Immune Therapy and Chemotherapy Response of Bladder Cancer Patients.
This study is the first to construct and validate an m7G-related lncRNA prognostic index in BC. In our results, MRLS has been validated through both internal and external cohorts as having independent prognostic value for BC patients. Moreover, there’s a significant correlation between MRLS and both immune therapy and chemotherapy. These results suggest that MRLS might be a potential biomarker. Through this analysis, we have initially discovered the potential important role of m7G-related lnRNA in the development and treatment process of BC. In the next steps, we will further explore the role of m7G in BC both in clinical and basic research.
Abstract Number: A0433
Identifying Endothelial-Related Molecular Subtypes in Bladder Cancer Patients
In this study, by integrating single-cell and bulk RNA sequencing data from the perspective of endothelial cells, we classified unique prognostically relevant molecular subtypes and key genes at the gene level, providing targets for precision medicine.
Abstract Number: A0904
Is obesity associated with prostate cancer risk through serum testosterone? A Mendelian randomization study.
This study employed Mendelian randomization with two-sample instrumental variables to assess the mediating effect of testosterone in the causal relationship between BMI and prostate cancer. The genetic evidence gathered in this study suggests that serum testosterone may mediate the impact of BMI on prostate cancer risk, providing a plausible mechanistic hypothesis for how obesity might reduce the risk of prostate cancer.
Abstract Number: A0377
Mitochondrial Metabolic Patterns Reveal Differences in Prostate Cancer Prognosis and Treatment Response
This study revealed the indispensable role of mitochondrial energy metabolism in the diversity and complexity development of the tumor microenvironment (TME). Assessing the mitochondrial energy metabolism patterns of tumors will help enhance our understanding of TME infiltrative features and guide more effective immune therapy strategies.
Abstract Number: A1191
Prognostic value of pre-treatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
The study suggests that the pre-treatment Lung Immune Prognostic Index (LIPI) has significant prognostic value for patients with metastatic hormone-sensitive prostate cancer (mHSPC) and castration-resistant prostate cancer (mCRPC). It holds potential to become a biomarker for prostate cancer.
Abstract Number:A1115
Evolutionary Relationship and Genomic Features of Prostatic Intraductal Carcinoma (IDC-P) and Acinar Adenocarcinoma (PAC)
This study has laid a solid molecular foundation for further exploring the malignant biological behavior of IDC-P. This study marks a significant step towards deciphering the biological characteristics of IDC-P. A deeper understanding of IDC-P will aid in the development of targeted drugs for this pathological subtype.
Abstract Number:A1150
ADP-Dependent Glucose Kinase (ADPGK) Regulates Metabolic Adaptability in Prostate Cancer Progression
This study has revealed for the first time that ADPGK is a driving factor in the progression of prostate cancer and is associated with poor prognosis in prostate cancer patients. ADPGK might accelerate glycolysis in prostate cancer by activating the ALDOC-AMPK signaling pathway, thereby promoting the progression of prostate cancer. The research results suggest that ADPGK can be considered as a target and marker for prostate cancer, providing a new approach for the treatment and prognosis of PCa.
Dr. Qiang Wei
West China Hospital of Sichuan University
Dr. Hao Zeng
West China Hospital of Sichuan University
Team Introduction
The Urologic Oncology Multidisciplinary Diagnosis and Treatment Team (MDT) of West China Hospital of Sichuan University was established in 2013 and is one of the earliest MDT teams in China that conforms to international advanced cancer treatment concepts. After nearly ten years of development, under the leadership of Professor Wei Qiang and Professor Zhou Qiao, the Urologic Oncology MDT of West China Hospital has become one of the four major demonstration bases for urologic oncology MDT in China. Adhering to the team concept of “developing together, creating the future together,” they focus on interactive clinical diagnosis and treatment, primarily centered on “patient service” and “clinical exploration.” They have provided numerous patients with personalized and precise comprehensive diagnosis and treatment plans, maximizing the benefits of survival and quality of life for patients.
The Urologic Oncology MDT currently encompasses 16 specialized areas with 47 members, including urology, oncology radiotherapy, oncology chemotherapy, pathology, radiology, nuclear medicine, endocrinology, vascular surgery, anesthesiology, cardiology, nephrology, hematology, psychological health center, and oncology nursing. In the past five years, they have served 1,582 urologic oncology patients, with an annual increase of 22.5%. Leveraging the national influence of West China Hospital and the team’s strong diagnostic and treatment capabilities, they have established patient follow-up systems for specific diseases like prostate cancer, renal cancer, and urothelial cancer. They have progressively established comprehensive clinical and bioinformatics databases for each urologic oncology specialty. Notably, as one of the five major medical centers worldwide focusing on intraductal prostate cancer (IDC-P) research, the prostate cancer sub-team has created the world’s largest IDC-P patient clinical information, radiomics, and genomics integrated database module, covering the entire lifecycle management process of prostate cancer patients. The median survival time for advanced prostate cancer is close to 80 months, surpassing international advanced levels. In 2020, the West China Urologic Oncology MDT team took the lead in establishing the CACA-GU Rare Renal Cancer Collaboration Group. With the support of domestic counterparts, they built the world’s largest comprehensive clinical and bioinformatics databases for succinate dehydrogenase-deficient renal cell carcinoma and TFE3 rearrangement-type renal cell carcinoma. They also initiated various prospective clinical explorations for rare pathological types of renal cancer, significantly improving the lives of this patient group.
The West China Urologic Oncology MDT team has collaborated effectively, obtaining more than 30 National Natural Science Foundation projects and leading 18 cancer-related clinical studies. In the past five years, they have published over 130 articles in influential journals including Cancer Cell, Nature Comm, Genome Med, PNAS, Clin Cancer Res, Cancer Res, Eur Urol, and J Urol. Furthermore, 48 clinical translational research achievements have been presented at important international urologic oncology conferences such as ASCO-GU, ASCO, AUA, EAU, and ESMO, continuously voicing the contributions from West China Urologic Oncology.
